• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Merck (MRK) Could Be 8% Undervalued Following Strong Phase 3 Cancer Data

    Simply Wall St·11/07/2026 21:15:04
    Listen to the news

    Merck (MRK) is back in focus after a run of late October oncology readouts, including Phase 3 wins for KEYTRUDA and sacituzumab tirumotecan in endometrial cancer and positive melanoma vaccine data with Moderna.

    Despite a modest pullback over the past week, Merck’s 30 day share price return of 2.76% and 90 day share price return of 14.12% point to strengthening momentum as oncology data, raised 2026 guidance, and fresh COPD and HIV updates add to an already strong 37.84% year to date share price gain and a 75.06% 1 year total shareholder return.

    Scan how Merck’s oncology momentum compares with other healthcare heavyweights by running your own shortlist through 35 healthcare AI stocks today.

    The question now is whether Merck’s recent 1 year and year to date surge has already priced in the oncology and vaccine story, or if the current valuation still leaves meaningful upside on the table.

    Most Popular Narrative: 8% Undervalued

    Merck’s most followed narrative pins fair value at $159.76 against a last close of $146.73, which frames the current oncology and vaccine optimism as only partly reflected in the share price. The gap is not huge, and it focuses attention on whether the next wave of products can carry earnings through the post KEYTRUDA period.

    Merck plans to bring over 20 new growth drivers to market in the coming years, and management now points to more than US$70b in non risk adjusted mid 2030s revenue potential from this next generation portfolio, which could support revenue and earnings resilience through and after the KEYTRUDA loss of exclusivity.

    See why 429 investors see Merck as 8% undervalued.

    Result: Fair Value of $159.76 (UNDERVALUED)

    Still, the Merck story can change quickly if the KEYTRUDA loss of exclusivity hits harder than analysts expect, or if newer oncology assets face clinical or regulatory setbacks.

    Find out about the key risks to this Merck narrative.

    Another View: What Merck’s P/E Is Telling You

    Merck’s fair value narrative leans on future earnings, yet today the stock trades on a P/E of 147.5x. That is far above the US Pharmaceuticals industry at 16x, the peer group at 35.1x, and even the fair ratio estimate of 57.3x. Is this rich multiple smart confidence or valuation risk you should treat carefully?

    See what the numbers say about this price — find out in our valuation breakdown.

    NYSE:MRK P/E Ratio as at Nov 2026
    NYSE:MRK P/E Ratio as at Nov 2026

    Next Steps

    Sentiment around Merck is mixed right now, with strong oncology excitement sitting alongside real questions about valuation and future execution. Act quickly and pressure test both sides of the story for yourself by reviewing the 2 key rewards and 5 important warning signs.

    Looking for more Merck investment ideas?

    If Merck has sharpened your focus on where capital might work harder next, do not stop here. Broaden your watchlist now and keep your options open.